Aprepitant
Aprepitant
CLINICAL USE
Prevention of acute and delayed nausea
and vomiting associated with moderate and
highly emetogenic cancer chemotherapy
DOSE IN NORMAL RENAL FUNCTION
125 mg once daily on day 1 followed by 80 mg
once daily on days 2 and 3
PHARMACOKINETICS
Molecular weight :
534.4
%Protein binding :
>95
%Excreted unchanged in urine :
0
Volume of distribution (L/kg) :
66 litres
half-life – normal/ESRD (hrs) :
9–13/Unchanged
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50 : Dose as in normal renal function
10 to 20 : Dose as in normal renal function
<10 :
Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD :
Not dialysed. Dose as in normal renal function
HD :
Not dialysed. Dose as in normal renal function
HDF/high flux :
Unlikely to be dialysed. Dose as in
normal renal function
CAV/VVHD :
Not dialysed. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Avoid concurrent administration with
pimozide or St John’s wort
Oestrogens and progestogens: may cause
contraceptive failure
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Less than 0.2% of a dose is recovered in
dialysate after haemodialysis
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home
.JPG)
